THE DIGITAL. Top trends SAVVY HCP

Transcription

1 Top trends THE DIGITAL SAVVY HCP 2017

2 02 / THE DIGITAL SAVVY HCP 2017 THE DIGITAL SAVVY HCP 2017 / 03 Executive Summary In our previous report THE DIGITAL SAVVY HCP 2015, we had noted a Respondent Demographics THE DIGITAL SAVVY HCP 2017 has participation of 1276 respondents, covering HCPs from USA, China, and RoW with a wide range of work experience. The HCPs are mainly divided into 2 functional areas General Medicine and Specialty. substantial increase in interactions through digital channels. In this year s survey, we are witnessing a continuation of this trend where digital channels are slowly but surely gaining ground over traditional ones; this year, the gap further narrowed to around 12%. China is the fastest growing digital country in the world with 61% of HCPs willing to participate in remote virtual engagements and over 75% recommending on-demand interactions versus a scheduled meeting.,, and are the top 3 digital channels preferred by HCPs worldwide. GeograPhy Mix of RespondEnts 40% 34% 26% USA China RoW Cardiologists, General Surgeons, Pulmonologists, Endocrinologists, and Oncologists are the top 5 specialists with the highest digital adoption. AstraZeneca, Elli Lilly, and GSK are perceived to be ahead of the curve by HCPs in meeting their digital engagement needs. Merck and Pfizer have witnessed a drop in their perception score versus the previous survey. Respondent Type Years of Clinical Practice of HCPs 43% General Physicians *Specialists Less than 10 years of experience 86% 14% More than 10 years of experience *Cardiology, Dermatology, Endocrinology, Emergency Medicine, Gastroenterology, Geriatrics, General Surgery, Neurology, Obstetrics and Gynecology, Oncology, Ophthalmology, Orthopedics, Pediatrics, Psychiatry, Pulmonology, Urology.

3 04 / THE DIGITAL SAVVY HCP 2017 THE DIGITAL SAVVY HCP 2017 / CHANNEL PREFERENCE Digital channels preferred by HCPs when accessing medical information Channel preference by regions Face-to-Face Tablet 62% 74% Face-to-Face Tablet 70% 71% 74% 81% /Webcasts Medical Science Liaison 61% 59% % 58% 62% 82% Rep-Triggered 53% 52% 53% 61% 91% Tele Rep Text Messaging 44% 46% Medical Science Liaison 14% 54% 58% 59% USA CHINA RoW Top 3 Digital Channels 45% 52% GLOBAL Rep- Triggered 41% 54% 53% 92%

4 06 / THE DIGITAL SAVVY HCP 2017 THE DIGITAL SAVVY HCP 2017 / HCP PREFERENCE TO ACCESS MEDICAL INFORMATION Frequency, time, and channels Optimal frequency is not more Optimal frequency is between PREFERRED TIME than one touch point per month 1 and 2 touch points per month Top Digital Channels Top Digital Channels 11:00 AM - 2:00 PM USA PREFERRED TIME 8:00 PM - 11:00 PM RoW Rep-Triggered Optimal frequency is not more than one touch point per month Top Digital Channels CHINA Rep-Triggered 5:00 PM - 8:00 PM PREFERRED TIME

5 08 / THE DIGITAL SAVVY HCP 2017 THE DIGITAL SAVVY HCP 2017 / HCP DIGITAL AFFINITY BY SPECIALISTs Digital readiness based on adoption globally Primary Care Physician Medicine/ Pediatrics Internal Medicine Family Medicine Pediatrics Neurology Dermatology Geriatrics Emergency Medicine Psychiatry Obstetrics and Gynecology General Surgery Pulmonology Urology Oncology Ophthalmology Gastroenterology Orthopedics Cardiology FENCE SITTERS (Low Affinity) AHEAD OF THE CURVE (High Affinity) Endocrinology

6 10 / THE DIGITAL SAVVY HCP 2017 THE DIGITAL SAVVY HCP 2017 / A Day in THE life of a physician AFTERNOON 11:00 AM-2:00 PM MORNING 8:00 AM-11:00 AM EVENING 5:00 PM-8:00 PM MSL Tele Rep USA Face-to-Face Tablet Rep-Triggered Tele Rep Remote Engagement (Live Rep) China KOL Webinars Face-to-Face Tablet Marketing Rep-Triggered RoW KOL Webinars Marketing Rep-Triggered KOL Webinars

7 REACH 12 / THE DIGITAL SAVVY HCP 2017 THE DIGITAL SAVVY HCP 2017 / CHANNEL EFFECTIVENESS Reach VERSUS Influence Efficiency of a channel based on its reach and influence on the minds of HCPs Top Pharma Performers in Digital Engagement Globally as perceived by HCPs AstraZeneca 1 100% Eli Lilly 2 GSK 3 Web Banners 75% Novartis 4 Marketing 5 Merck Remote Engagement 50% 6 Pfizer Text Messaging 7 JnJ 25% Brand Face-to-Face Tablet Sanofi 8 Rep- Triggered Tele Rep MSL Roche 9 0% INFLUENCE 25% 50% 75% 100%

8 14 / THE DIGITAL SAVVY HCP 2017 THE DIGITAL SAVVY HCP 2017 / 15 Disclaimer All findings, inferences, and data shared in this report are solely the views of the respondents and may, or may not represent the views of any organization. PharmaFuture bears no liability in any capacity to the authenticity, accuracy, or completeness of the information shared. PharmaFuture has in no way modified or influenced the results presented in this report, which contains information in summary form and is therefore intended for general guidance only. It is not intended to be a substitute for detailed research or the exercise of professional judgment. PharmaFuture is not liable for any loss occasioned to any person acting, or refraining from acting, as a result of any material in this publication. If you intend to reuse, copy, or reproduce any content in the report in any form, due credit has to be given to Indegene by mentioning Source: THE DIGITAL SAVVY HCP 2017 as the source of information for all reproductions. To reproduce, copy, or use any or all parts of this report for commercial, non-commercial, or academic purposes, express written permission must be sought by writing to info@pharmafuture.org. NOTES

9 For general inquires and reproduction requests contact